📊 AURX Key Takeaways
Investment Thesis
Nuo Therapeutics exhibits severe financial distress with negative stockholders' equity of -$419.6K, indicating the company is technically insolvent. Despite 124.3% revenue growth, the company is burning cash at an alarming rate (-$673.9K free cash flow) while maintaining massive operating losses (-87.4% margin), and with only $514.8K in cash reserves against $2.3M in liabilities, the company faces imminent solvency crisis.
AURX Strengths
- Strong revenue growth of 124.3% YoY demonstrates market demand for products
- Gross margin of 69.0% indicates pricing power and product viability at production level
- No long-term debt reduces refinancing risk in near term
AURX Risks
- Negative stockholders' equity of -$419.6K indicates technical insolvency and potential shareholder dilution
- Severe cash burn of -$673.9K FCF with only $514.8K cash on hand provides less than one quarter of runway
- Operating losses of -$1.9M despite revenue growth indicate inability to achieve operational efficiency
- Liabilities of $2.3M exceed total assets of $1.9M by $400K creating balance sheet crisis
- Negative operating cash flow of -$442.3K shows business cannot fund operations internally
Key Metrics to Watch
- Cash position depletion rate and runway to insolvency
- Operating loss trajectory and path to profitability timeline
- Revenue growth sustainability and gross margin maintenance
- Capital requirements and dilution from equity financing
- Working capital management and accounts payable/receivable trends
AURX Financial Metrics
💡 AI Analyst Insight
Nuo Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
AURX Profitability Ratios
AURX vs Healthcare Sector
How Nuo Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AURX Balance Sheet & Liquidity
AURX 5-Year Financial Trend
5-Year Trend Summary: Nuo Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.05 indicates the company is currently unprofitable.
AURX Growth Metrics (YoY)
AURX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $371.0K | -$537.9K | $-0.01 |
| Q2 2025 | $364.8K | -$540.1K | $-0.01 |
| Q1 2025 | $234.6K | -$708.8K | $-0.02 |
| Q3 2024 | $232.2K | -$540.1K | $-0.01 |
| Q2 2024 | $118.2K | -$540.1K | $-0.01 |
| Q1 2024 | $61.1K | -$708.8K | $-0.02 |
| Q3 2023 | $38.3K | -$375.4K | $-0.02 |
| Q2 2023 | N/A | -$375.4K | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AURX Capital Allocation
AURX SEC Filings
Access official SEC EDGAR filings for Nuo Therapeutics, Inc. (CIK: 0001091596)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AURX
What is the AI rating for AURX?
Nuo Therapeutics, Inc. (AURX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AURX's key strengths?
Strong revenue growth of 124.3% YoY demonstrates market demand for products. Gross margin of 69.0% indicates pricing power and product viability at production level.
What are the risks of investing in AURX?
Negative stockholders' equity of -$419.6K indicates technical insolvency and potential shareholder dilution. Severe cash burn of -$673.9K FCF with only $514.8K cash on hand provides less than one quarter of runway.
What is AURX's revenue and growth?
Nuo Therapeutics, Inc. reported revenue of $2.2M.
Does AURX pay dividends?
Nuo Therapeutics, Inc. does not currently pay dividends.
Where can I find AURX SEC filings?
Official SEC filings for Nuo Therapeutics, Inc. (CIK: 0001091596) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AURX's EPS?
Nuo Therapeutics, Inc. has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.